Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
26
ATOS Quote, Financials, Valuation and Earnings
Last price:
$4.41
Seasonality move
:
3.3%
Day range:
$4.20 - $4.55
52-week range:
$3.76 - $19.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.76x
Volume:
78.8K
Avg. volume:
196.2K
1-year change:
-66.44%
Market cap:
$38.1M
Revenue:
--
EPS (TTM):
-$0.23
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ATOS
Atossa Therapeutics, Inc.
|
-- | -$1.14 | -- | -1919.23% | $80.00 |
|
ABEO
Abeona Therapeutics, Inc.
|
$5.6M | -$0.34 | -97.62% | -57.23% | $20.64 |
|
CLCS
Cell Source, Inc.
|
-- | -- | -- | -- | -- |
|
CLDX
Celldex Therapeutics, Inc.
|
$1.5M | -$1.00 | -9.83% | -30.49% | $53.36 |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
$1.5M | -$0.70 | 3650% | -11.09% | $11.00 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ATOS
Atossa Therapeutics, Inc.
|
$4.42 | $80.00 | $38.1M | -- | $0.00 | 0% | -- |
|
ABEO
Abeona Therapeutics, Inc.
|
$5.29 | $20.64 | $286.7M | 4.54x | $0.00 | 0% | 715.16x |
|
CLCS
Cell Source, Inc.
|
$0.8500 | -- | $38.3M | -- | $0.00 | 0% | -- |
|
CLDX
Celldex Therapeutics, Inc.
|
$23.54 | $53.36 | $1.6B | -- | $0.00 | 0% | 601.06x |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
$2.06 | $11.00 | $7.6M | -- | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.29 | $5.50 | $40.2M | -- | $0.00 | 0% | 4.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ATOS
Atossa Therapeutics, Inc.
|
-- | 0.662 | -- | 6.32x |
|
ABEO
Abeona Therapeutics, Inc.
|
12.34% | -1.035 | 8.71% | 9.35x |
|
CLCS
Cell Source, Inc.
|
-- | -0.372 | -- | -- |
|
CLDX
Celldex Therapeutics, Inc.
|
0.44% | 1.179 | 0.15% | 12.42x |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
1.77% | 0.329 | 4.23% | 7.51x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ATOS
Atossa Therapeutics, Inc.
|
-$4K | -$9.3M | -47.46% | -47.46% | -- | -$6M |
|
ABEO
Abeona Therapeutics, Inc.
|
-$1.4M | -$24M | 70.47% | 88.36% | -5698% | -$23.7M |
|
CLCS
Cell Source, Inc.
|
-- | -$831.6K | -- | -- | -- | -$639K |
|
CLDX
Celldex Therapeutics, Inc.
|
-$824K | -$73.6M | -32.02% | -32.17% | -8747.53% | -$49.1M |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
-$38.2K | -$2.5M | -34.13% | -34.44% | 82.56% | -$1.3M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Atossa Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ATOS or ABEO?
Abeona Therapeutics, Inc. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of --. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Abeona Therapeutics, Inc.'s return on equity of 88.36%.
Company Gross Margin Earnings Per Share Invested Capital ATOSAtossa Therapeutics, Inc.-- -$0.07 $49.8M ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M -
What do Analysts Say About ATOS or ABEO?
Atossa Therapeutics, Inc. has a consensus price target of $80.00, signalling upside risk potential of 1455.43%. On the other hand Abeona Therapeutics, Inc. has an analysts' consensus of $20.64 which suggests that it could grow by 290.22%. Given that Atossa Therapeutics, Inc. has higher upside potential than Abeona Therapeutics, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Abeona Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ATOSAtossa Therapeutics, Inc.3 0 0 ABEOAbeona Therapeutics, Inc.6 0 0 -
Is ATOS or ABEO More Risky?
Atossa Therapeutics, Inc. has a beta of 1.364, which suggesting that the stock is 36.379% more volatile than S&P 500. In comparison Abeona Therapeutics, Inc. has a beta of 1.175, suggesting its more volatile than the S&P 500 by 17.515%.
-
Which is a Better Dividend Stock ATOS or ABEO?
Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abeona Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Abeona Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATOS or ABEO?
Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than Abeona Therapeutics, Inc. quarterly revenues of --. Atossa Therapeutics, Inc.'s net income of -$8.7M is lower than Abeona Therapeutics, Inc.'s net income of -$5.2M. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Abeona Therapeutics, Inc.'s PE ratio is 4.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus 715.16x for Abeona Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATOSAtossa Therapeutics, Inc.-- -- -- -$8.7M ABEOAbeona Therapeutics, Inc.715.16x 4.54x -- -$5.2M
-
Which has Higher Returns ATOS or CLCS?
Cell Source, Inc. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of --. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Cell Source, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATOSAtossa Therapeutics, Inc.-- -$0.07 $49.8M CLCSCell Source, Inc.-- -$0.04 -- -
What do Analysts Say About ATOS or CLCS?
Atossa Therapeutics, Inc. has a consensus price target of $80.00, signalling upside risk potential of 1455.43%. On the other hand Cell Source, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Atossa Therapeutics, Inc. has higher upside potential than Cell Source, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Cell Source, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ATOSAtossa Therapeutics, Inc.3 0 0 CLCSCell Source, Inc.0 0 0 -
Is ATOS or CLCS More Risky?
Atossa Therapeutics, Inc. has a beta of 1.364, which suggesting that the stock is 36.379% more volatile than S&P 500. In comparison Cell Source, Inc. has a beta of -225.097, suggesting its less volatile than the S&P 500 by 22609.671%.
-
Which is a Better Dividend Stock ATOS or CLCS?
Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cell Source, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Cell Source, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATOS or CLCS?
Atossa Therapeutics, Inc. quarterly revenues are --, which are larger than Cell Source, Inc. quarterly revenues of --. Atossa Therapeutics, Inc.'s net income of -$8.7M is lower than Cell Source, Inc.'s net income of -$1.4M. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Cell Source, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus -- for Cell Source, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATOSAtossa Therapeutics, Inc.-- -- -- -$8.7M CLCSCell Source, Inc.-- -- -- -$1.4M
-
Which has Higher Returns ATOS or CLDX?
Celldex Therapeutics, Inc. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of -7753.43%. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.
Company Gross Margin Earnings Per Share Invested Capital ATOSAtossa Therapeutics, Inc.-- -$0.07 $49.8M CLDXCelldex Therapeutics, Inc.-19.59% -$1.01 $601M -
What do Analysts Say About ATOS or CLDX?
Atossa Therapeutics, Inc. has a consensus price target of $80.00, signalling upside risk potential of 1455.43%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.36 which suggests that it could grow by 126.67%. Given that Atossa Therapeutics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Celldex Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ATOSAtossa Therapeutics, Inc.3 0 0 CLDXCelldex Therapeutics, Inc.12 2 0 -
Is ATOS or CLDX More Risky?
Atossa Therapeutics, Inc. has a beta of 1.364, which suggesting that the stock is 36.379% more volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.242, suggesting its more volatile than the S&P 500 by 24.184%.
-
Which is a Better Dividend Stock ATOS or CLDX?
Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATOS or CLDX?
Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than Celldex Therapeutics, Inc. quarterly revenues of --. Atossa Therapeutics, Inc.'s net income of -$8.7M is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus 601.06x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATOSAtossa Therapeutics, Inc.-- -- -- -$8.7M CLDXCelldex Therapeutics, Inc.601.06x -- -- -$67M
-
Which has Higher Returns ATOS or KPRX?
Kiora Pharmaceuticals, Inc. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of 84.08%. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Kiora Pharmaceuticals, Inc.'s return on equity of -34.44%.
Company Gross Margin Earnings Per Share Invested Capital ATOSAtossa Therapeutics, Inc.-- -$0.07 $49.8M KPRXKiora Pharmaceuticals, Inc.-- $0.01 $22.8M -
What do Analysts Say About ATOS or KPRX?
Atossa Therapeutics, Inc. has a consensus price target of $80.00, signalling upside risk potential of 1455.43%. On the other hand Kiora Pharmaceuticals, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 433.98%. Given that Atossa Therapeutics, Inc. has higher upside potential than Kiora Pharmaceuticals, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Kiora Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ATOSAtossa Therapeutics, Inc.3 0 0 KPRXKiora Pharmaceuticals, Inc.0 0 0 -
Is ATOS or KPRX More Risky?
Atossa Therapeutics, Inc. has a beta of 1.364, which suggesting that the stock is 36.379% more volatile than S&P 500. In comparison Kiora Pharmaceuticals, Inc. has a beta of -0.819, suggesting its less volatile than the S&P 500 by 181.948%.
-
Which is a Better Dividend Stock ATOS or KPRX?
Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiora Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Kiora Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATOS or KPRX?
Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than Kiora Pharmaceuticals, Inc. quarterly revenues of --. Atossa Therapeutics, Inc.'s net income of -$8.7M is lower than Kiora Pharmaceuticals, Inc.'s net income of $26.8K. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Kiora Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus -- for Kiora Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATOSAtossa Therapeutics, Inc.-- -- -- -$8.7M KPRXKiora Pharmaceuticals, Inc.-- -- -- $26.8K
-
Which has Higher Returns ATOS or PSTV?
Plus Therapeutics, Inc. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of -316.61%. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATOSAtossa Therapeutics, Inc.-- -$0.07 $49.8M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About ATOS or PSTV?
Atossa Therapeutics, Inc. has a consensus price target of $80.00, signalling upside risk potential of 1455.43%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1778.42%. Given that Plus Therapeutics, Inc. has higher upside potential than Atossa Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Atossa Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ATOSAtossa Therapeutics, Inc.3 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is ATOS or PSTV More Risky?
Atossa Therapeutics, Inc. has a beta of 1.364, which suggesting that the stock is 36.379% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock ATOS or PSTV?
Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATOS or PSTV?
Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Atossa Therapeutics, Inc.'s net income of -$8.7M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus 4.69x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATOSAtossa Therapeutics, Inc.-- -- -- -$8.7M PSTVPlus Therapeutics, Inc.4.69x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 2.23% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 0.38% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is up 0.8% over the past day.
